The startup develops stem cell and exosome therapies that utilize an intrinsic stem cell strategy to isolate and expand lung stem cells in vitro, enabling mass production without antigenic sorting. This approach provides physicians with effective therapeutic options for pulmonary fibrosis and other degenerative lung diseases.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pulmonary fibrosis, affecting over 100,000 Americans, leads to progressive scarring and damage of lung tissue, resulting in impaired lung function. Current treatments offer limited efficacy, primarily slowing disease progression with significant side effects, while lung transplants are constrained by cost and donor availability.
Solution
BreStem Therapeutics is developing cell-based and cell-free therapies utilizing Lung Spheroid Cells (LSCs) to address pulmonary fibrosis and other degenerative lung diseases. Their autologous LSC therapy isolates and expands lung stem cells in vitro, offering a novel approach to lung regeneration. The lead candidate, BRS101, is currently in Phase 1 clinical trials for idiopathic pulmonary fibrosis (IPF). BreStem is also developing BRS201, a cell-free therapy utilizing secretome and exosomes derived from lung stem cells, for off-the-shelf regenerative treatments.
Target Audience
The primary target audience includes individuals living with pulmonary fibrosis, medical professionals specializing in pulmonary diseases, and investors interested in regenerative medicine.
Features
- Autologous Lung Spheroid Cells (LSCs) therapy for cell-based lung regeneration.
- BRS101: Lead investigational new drug in Phase 1 clinical trial for IPF treatment.
- BRS201: Cell-free therapy using secretome and exosomes derived from lung stem cells.
- Rapid method for in-vitro isolation and expansion of lung stem cells.
- "From the lung to the lung" intrinsic stem cell strategy.
- Eliminates the need for antigenic sorting and purification of stem cells.
- Potential for mass manufacturing of lung stem cells.